vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Maison Solutions Inc. (MSS). Click either name above to swap in a different company.
Maison Solutions Inc. is the larger business by last-quarter revenue ($27.6M vs $16.1M, roughly 1.7× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -18.0%, a 10.2% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -10.9%). Over the past eight quarters, Maison Solutions Inc.'s revenue compounded faster (42.5% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
DERM vs MSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $27.6M |
| Net Profit | $-1.2M | $-5.0M |
| Gross Margin | — | 23.4% |
| Operating Margin | -2.8% | -4.9% |
| Net Margin | -7.8% | -18.0% |
| Revenue YoY | 27.3% | -10.9% |
| Net Profit YoY | -182.0% | -1840.5% |
| EPS (diluted) | $-0.04 | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $27.6M | ||
| Q3 25 | $17.0M | $27.2M | ||
| Q2 25 | $15.0M | $34.4M | ||
| Q1 25 | $13.1M | $32.3M | ||
| Q4 24 | $12.6M | $29.4M | ||
| Q3 24 | $14.6M | $28.2M | ||
| Q2 24 | $14.9M | $16.9M | ||
| Q1 24 | $13.0M | $13.6M |
| Q4 25 | $-1.2M | $-5.0M | ||
| Q3 25 | $-2.3M | $-1.5M | ||
| Q2 25 | $-3.8M | $-287.4K | ||
| Q1 25 | $-4.1M | $1.0M | ||
| Q4 24 | $1.5M | $-256.0K | ||
| Q3 24 | $-2.4M | $700.9K | ||
| Q2 24 | $-3.4M | $-2.8M | ||
| Q1 24 | $-10.4M | $-549.0K |
| Q4 25 | — | 23.4% | ||
| Q3 25 | — | 24.1% | ||
| Q2 25 | — | 9.5% | ||
| Q1 25 | — | 21.8% | ||
| Q4 24 | 82.3% | 26.9% | ||
| Q3 24 | 63.9% | 28.9% | ||
| Q2 24 | 56.0% | 13.0% | ||
| Q1 24 | 47.7% | 23.4% |
| Q4 25 | -2.8% | -4.9% | ||
| Q3 25 | -9.0% | 0.7% | ||
| Q2 25 | -19.2% | -15.9% | ||
| Q1 25 | -25.3% | 3.7% | ||
| Q4 24 | 17.7% | 3.2% | ||
| Q3 24 | -19.8% | 7.3% | ||
| Q2 24 | -19.7% | -14.4% | ||
| Q1 24 | -77.4% | -2.3% |
| Q4 25 | -7.8% | -18.0% | ||
| Q3 25 | -13.6% | -5.7% | ||
| Q2 25 | -25.3% | -0.8% | ||
| Q1 25 | -31.0% | 3.1% | ||
| Q4 24 | 12.1% | -0.9% | ||
| Q3 24 | -16.3% | 2.5% | ||
| Q2 24 | -22.6% | -16.4% | ||
| Q1 24 | -80.1% | -4.0% |
| Q4 25 | $-0.04 | $-0.23 | ||
| Q3 25 | $-0.09 | $-0.08 | ||
| Q2 25 | $-0.16 | $-0.02 | ||
| Q1 25 | $-0.18 | $0.06 | ||
| Q4 24 | $0.10 | $-0.01 | ||
| Q3 24 | $-0.12 | $0.04 | ||
| Q2 24 | $-0.17 | $-0.16 | ||
| Q1 24 | $-0.53 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | — |
| Total DebtLower is stronger | $25.3M | $2.6M |
| Stockholders' EquityBook value | $31.9M | $11.6M |
| Total Assets | $94.6M | $75.4M |
| Debt / EquityLower = less leverage | 0.79× | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | — | ||
| Q3 25 | $24.9M | $1.1M | ||
| Q2 25 | $20.3M | $775.4K | ||
| Q1 25 | $21.1M | $445.4K | ||
| Q4 24 | $20.3M | $355.7K | ||
| Q3 24 | $22.5M | $588.9K | ||
| Q2 24 | $23.9M | $2.1M | ||
| Q1 24 | $24.1M | $9.4M |
| Q4 25 | $25.3M | $2.6M | ||
| Q3 25 | $25.2M | $2.6M | ||
| Q2 25 | $25.1M | $2.6M | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | $2.5M | ||
| Q2 24 | $19.7M | $2.6M | ||
| Q1 24 | $14.7M | $2.6M |
| Q4 25 | $31.9M | $11.6M | ||
| Q3 25 | $25.9M | $10.1M | ||
| Q2 25 | $19.2M | $11.7M | ||
| Q1 25 | $21.5M | $12.0M | ||
| Q4 24 | $20.1M | $10.9M | ||
| Q3 24 | $10.9M | $11.2M | ||
| Q2 24 | $11.3M | $10.5M | ||
| Q1 24 | $13.0M | $13.3M |
| Q4 25 | $94.6M | $75.4M | ||
| Q3 25 | $85.2M | $73.3M | ||
| Q2 25 | $81.2M | $77.4M | ||
| Q1 25 | $85.0M | $82.7M | ||
| Q4 24 | $80.2M | $82.7M | ||
| Q3 24 | $64.0M | $82.1M | ||
| Q2 24 | $65.2M | $82.4M | ||
| Q1 24 | $66.6M | $44.2M |
| Q4 25 | 0.79× | 0.22× | ||
| Q3 25 | 0.97× | 0.26× | ||
| Q2 25 | 1.30× | 0.22× | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | 0.23× | ||
| Q2 24 | 1.75× | 0.24× | ||
| Q1 24 | 1.13× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-1.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-1.7M | ||
| Q3 25 | $-2.4M | $1.1M | ||
| Q2 25 | $-942.0K | $-1.6M | ||
| Q1 25 | $-2.8M | $1.7M | ||
| Q4 24 | $2.2M | $1.1M | ||
| Q3 24 | $-1.2M | $3.6M | ||
| Q2 24 | $-5.2M | $-2.6M | ||
| Q1 24 | $-5.0M | $-1.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.66× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | 5.12× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
